Protective Effects of Autologous Bone Marrow Mononuclear Cells After Administering T-PA in an Embolic Stroke Model

Overview

Journal Transl Stroke Res

Publisher Springer

Date 2017 Aug 25

PMID 28836238

Citations 16

Authors

Bing Yang

Weilang Li

Nikunj Satani

Duyen M Nghiem

XiaoPei Xi

Jaroslaw Aronowski

Sean I Savitz

Affiliations

Soon will be listed here.

Abstract

Tissue plasminogen activator (t-PA) is the only FDA-approved drug for acute ischemic stroke but poses risk for hemorrhagic transformation (HT). Cell therapy has been investigated as a potential therapy to improve recovery after stroke by the modulation of inflammatory responses and the improvement of blood-brain barrier (BBB) integrity, both of which are associated with HT after t-PA. In our present study, we studied the effect of autologous bone marrow mononuclear cells (MNCs) in an embolic stroke model. We administered MNCs in a rat embolic stroke 2 h after administering t-PA. We observed that even though autologous MNCs did not alter the incidence of HT, they decreased the severity of HT and reduced BBB permeability. One possible mechanism could be through the inhibition of MMP3 released by astrocytes via JAK/STAT pathway as shown by our in vitro cell interaction studies.

Citing Articles

Brain repair mechanisms after cell therapy for stroke.

Rust R, Nih L, Liberale L, Yin H, El Amki M, Ong L Brain. 2024; 147(10):3286-3305.

PMID: 38916992 PMC: 11449145. DOI: 10.1093/brain/awae204.

Mononuclear cell therapy of neonatal hypoxic-ischemic encephalopathy in preclinical versus clinical studies: a systematic analysis of therapeutic efficacy and study design.

Scrutton A, Ollis F, Boltze J Neuroprotection. 2024; 1(2):143-159.

PMID: 38213793 PMC: 7615506. DOI: 10.1002/nep3.29.

Clarifying the mechanism of apigenin against blood-brain barrier disruption in ischemic stroke using systems pharmacology.

Wang X, Yu Z, Dong F, Li J, Niu P, Ta Q Mol Divers. 2023; 28(2):609-630.

PMID: 36949297 DOI: 10.1007/s11030-023-10607-9.

Emerging Targets for Modulation of Immune Response and Inflammation in Stroke.

Thapa K, Shivam K, Khan H, Kaur A, Dua K, Singh S Neurochem Res. 2023; 48(6):1663-1690.

PMID: 36763312 DOI: 10.1007/s11064-023-03875-2.

Preconditioning With Intermittent Hypobaric Hypoxia Attenuates Stroke Damage and Modulates Endocytosis in Residual Neurons.

Wan Y, Huang L, Liu Y, Ji W, Li C, Ge R Front Neurol. 2022; 12:750908.

PMID: 34975719 PMC: 8715922. DOI: 10.3389/fneur.2021.750908.

References

Neumann-Haefelin C, Brinker G, Uhlenkuken U, Pillekamp F, Hossmann K, Hoehn M . Prediction of hemorrhagic transformation after thrombolytic therapy of clot embolism: an MRI investigation in rat brain. Stroke. 2002; 33(5):1392-8. DOI: 10.1161/01.str.0000014619.59851.65. View

Yang B, Parsha K, Schaar K, Satani N, Xi X, Aronowski J . Cryopreservation of Bone Marrow Mononuclear Cells Alters Their Viability and Subpopulation Composition but Not Their Treatment Effects in a Rodent Stroke Model. Stem Cells Int. 2016; 2016:5876836. PMC: 4926012. DOI: 10.1155/2016/5876836. View

. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke. 1997; 28(11):2109-18. DOI: 10.1161/01.str.28.11.2109. View

Moniche F, Rosado-de-Castro P, Escudero I, Zapata E, de la Torre Laviana F, Mendez-Otero R . Increasing Dose of Autologous Bone Marrow Mononuclear Cells Transplantation Is Related to Stroke Outcome: Results from a Pooled Analysis of Two Clinical Trials. Stem Cells Int. 2016; 2016:8657173. PMC: 4972913. DOI: 10.1155/2016/8657173. View

Savitz S, Misra V, Kasam M, Juneja H, Cox Jr C, Alderman S . Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol. 2011; 70(1):59-69. DOI: 10.1002/ana.22458. View

Leigh R, Jen S, Hillis A, Krakauer J, Barker P . Pretreatment blood-brain barrier damage and post-treatment intracranial hemorrhage in patients receiving intravenous tissue-type plasminogen activator. Stroke. 2014; 45(7):2030-5. PMC: 4120660. DOI: 10.1161/STROKEAHA.114.005249. View

Bedi S, Walker P, Shah S, Jimenez F, Thomas C, Smith P . Autologous bone marrow mononuclear cells therapy attenuates activated microglial/macrophage response and improves spatial learning after traumatic brain injury. J Trauma Acute Care Surg. 2013; 75(3):410-6. PMC: 4086922. DOI: 10.1097/TA.0b013e31829617c6. View

Rodriguez-Frutos B, Otero-Ortega L, Gutierrez-Fernandez M, Fuentes B, Ramos-Cejudo J, Diez-Tejedor E . Stem Cell Therapy and Administration Routes After Stroke. Transl Stroke Res. 2016; 7(5):378-87. DOI: 10.1007/s12975-016-0482-6. View

. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333(24):1581-7. DOI: 10.1056/NEJM199512143332401. View

10.

Hess D, Wechsler L, Clark W, Savitz S, Ford G, Chiu D . Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017; 16(5):360-368. DOI: 10.1016/S1474-4422(17)30046-7. View

11.

Yang Y, Rosenberg G . Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke. 2011; 42(11):3323-8. PMC: 3584169. DOI: 10.1161/STROKEAHA.110.608257. View

12.

Brinker G, Pillekamp F, Hossmann K . Brain hemorrhages after rt-PA treatment of embolic stroke in spontaneously hypertensive rats. Neuroreport. 1999; 10(9):1943-6. DOI: 10.1097/00001756-199906230-00027. View

13.

Fan X, Qiu J, Yu Z, Dai H, Singhal A, Lo E . A rat model of studying tissue-type plasminogen activator thrombolysis in ischemic stroke with diabetes. Stroke. 2011; 43(2):567-70. PMC: 3508716. DOI: 10.1161/STROKEAHA.111.635250. View

14.

Neuhaus W, Gaiser F, Mahringer A, Franz J, Riethmuller C, Forster C . The pivotal role of astrocytes in an in vitro stroke model of the blood-brain barrier. Front Cell Neurosci. 2014; 8:352. PMC: 4211409. DOI: 10.3389/fncel.2014.00352. View

15.

Dijkhuizen R, Asahi M, Wu O, Rosen B, Lo E . Delayed rt-PA treatment in a rat embolic stroke model: diagnosis and prognosis of ischemic injury and hemorrhagic transformation with magnetic resonance imaging. J Cereb Blood Flow Metab. 2001; 21(8):964-71. DOI: 10.1097/00004647-200108000-00009. View

16.

Liu H, Wang Y, Xiao Y, Hua Z, Cheng J, Jia J . Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke. Transl Stroke Res. 2016; 7(3):209-19. DOI: 10.1007/s12975-016-0459-5. View

17.

Jickling G, Liu D, Stamova B, Ander B, Zhan X, Lu A . Hemorrhagic transformation after ischemic stroke in animals and humans. J Cereb Blood Flow Metab. 2013; 34(2):185-99. PMC: 3915212. DOI: 10.1038/jcbfm.2013.203. View

18.

Dijkhuizen R, Asahi M, Wu O, Rosen B, Lo E . Rapid breakdown of microvascular barriers and subsequent hemorrhagic transformation after delayed recombinant tissue plasminogen activator treatment in a rat embolic stroke model. Stroke. 2002; 33(8):2100-4. DOI: 10.1161/01.str.0000023534.37670.f7. View

19.

Iihoshi S, Honmou O, Houkin K, Hashi K, Kocsis J . A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats. Brain Res. 2004; 1007(1-2):1-9. DOI: 10.1016/j.brainres.2003.09.084. View

20.

Kastrup A, Groschel K, Ringer T, Redecker C, Cordesmeyer R, Witte O . Early disruption of the blood-brain barrier after thrombolytic therapy predicts hemorrhage in patients with acute stroke. Stroke. 2008; 39(8):2385-7. DOI: 10.1161/STROKEAHA.107.505420. View